At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 17, 2026 at 06:00 ET
Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib, showing a 44% objective response rate and 94% disease control rate with its investigational combination of darlifarnib and cabozantinib. The results suggest potential to overcome resistance to VEGF TKI therapy in a heavily pretreated population, with durable responses observed and a manageable safety profile. The data were presented at IKCS: Europe and discussed in a virtual investor event.
- Preliminary data from 16 ccRCC patients previously treated with cabozantinib showed a 44% objective response rate (ORR) and 94% disease control rate (DCR).
- Tumor shrinkage occurred in 75% of patients, with reductions ranging from 32% to 47% among responders.
- Treatment durations ranged up to 56 weeks, with one-third of patients still on therapy at data cutoff.
- Darlifarnib is being evaluated in combination with cabozantinib in the ongoing FIT-001 trial, with dose expansion underway.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access